Simple Urine Test Helps Predict Kidney Transplant Outcomes

Levels of CXCL9 protein in the urine of kidney transplant recipients can differentiate those at low risk of developing kidney injury from those at high risk, say researchers. The results also suggest that low levels of this protein, called CXCL9, can rule out rejection as a cause of kidney injury. The study appears online Aug. 22 in the American Journal of Transplantation. The work was funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

To prevent rejection, kidney transplant recipients typically take immunosuppressive drugs every day. However, these drugs can cause kidney damage and lead to other serious side effects such as cancer, infection and infertility. Even with immunosuppressive therapy, 10 to 15 percent of kidney recipients experience rejection during the first year after transplantation.

About Transplantation
Since the early times, the novel idea of transplanting tissues and other body parts from one organism to the other has captured the imagination of successive generations.

Currently, the only definitive way to distinguish rejection from other causes of kidney injury is by performing a biopsy, in which doctors remove a small piece of kidney tissue to look for rejection-associated damage. Although this procedure is generally considered safe, it carries some minor risks for the patient and does not always provide an accurate impression of the overall state of the kidney.

"A noninvasive urine test to accurately monitor the risk of kidney rejection could dramatically reduce the need for biopsies and possibly enable doctors to safely reduce immunosuppressive therapy in some patients," said NIAID Director Anthony S. Fauci, M.D. "The results of this study support the further development of noninvasive tests for the detection and management of transplant rejection."

In this multicenter Clinical Trials in Organ Transplantation study, doctors periodically collected urine samples from 280 adult and child kidney transplant recipients for two years after transplantation. Investigators led by Peter Heeger, M.D., of the Icahn School of Medicine at Mount Sinai in New York City, and Donald Hricik, M.D., of Case Western Reserve University in Cleveland, measured the urinary levels of molecules that had previously been associated with rejection. These included two proteins and nine messenger RNAs (mRNAs)—intermediary molecules in the construction of proteins from genes. They identified CXCL9 protein and CXCL9 mRNA as potential biomarkers—molecules that indicate the effect or progress of a disease—for the diagnosis of rejection.

Quiz on Kidney Stones
Kidney stones or calculus produces the most severe form of pain in humans. The pain has often been described to be worse than childbirth, broken bones, gunshot wounds, burns, or surgery. Once you form a kidney stone you are always susceptible to another stone. Take this quiz to find out how much do you know about stone disease. Once you complete find out how you fared compared to others who have taken the quiz.

After further testing, the researchers found that CXCL9 protein was better at ruling out rejection than any of the mRNAs tested. Low levels of the protein biomarker also could identify patients likely to have stable long-term kidney function. Transplant recipients with low urinary CXCL9 protein six months after transplantation were unlikely to experience rejection or loss of kidney function over the next 18 months. In addition, detection of the protein in the urine of transplant recipients was more straightforward than measuring mRNA levels. While proteins can be measured directly in urine, mRNAs must first be extracted from urine samples. The researchers obtained sufficient mRNA from just 76 percent of samples, highlighting the technical challenges of extraction.

"The relative ease of measuring urinary proteins suggests that developing a protein-based urine test for use in clinical practice would be less complicated than an mRNA test," said Daniel Rotrosen, M.D., director of NIAID's Division of Allergy, Immunology and Transplantation. "There is strong precedent for the development and use of tests that measure urinary proteins, such as home pregnancy tests."

Animation On Key Hole Surgery for Kidney Stone Removal or Percutaneous Nephrolithotomy (PCNL)
Graphical explanation of stone removal from the kidney with a minimally invasive procedure called Percutaneous Nephrolithotomy. This is a major endoscopic procedure needing hospitalization.

CXCL9 protein levels also may be useful for predicting and monitoring transplant rejection. The investigators noted that urinary CXCL9 levels began to increase up to 30 days before clinical signs of kidney injury, which could allow doctors to intervene early to potentially avoid rejection-associated kidney damage. The protein levels began to drop after treatment for rejection, suggesting that the urine test could be used to monitor treatment progress.

"Development of noninvasive tests to detect immune activation before kidney damage occurs would help guide the care of kidney transplant recipients," said NIAID Transplantation Branch Chief Nancy Bridges, M.D., a co-author of the paper. "Clinical application of the findings from this study could help avoid unnecessary biopsies and excess immunosuppression."

Use of ADT For Treatment of Prostate Cancer Linked With Increased Risk of Kidney Injury: Study
In a study that included more than 10,000 men with nonmetastatic prostate cancer, use of ADT was associated with a significantly increased risk of acute kidney injury.

Source-Eurekalert